Mark Agulnik

Mark Agulnik, MD, is a Clinical Professor at the Keck School of Medicine, University of Southern California, serving as Vice Chair for Faculty Development and Section Chief of Sarcomas & Melanoma in the Department of Medicine. His research focuses on Medical Oncology, Immunotherapy, and Targeted Therapy for sarcomas and head/neck cancers.

• Primary Affiliation: Keck School of Medicine, University of Southern California
• Leadership Roles: Vice Chair for Faculty Development, Section Chief of Sarcomas & Melanoma

Research Interests include:

• Development of novel immunotherapies for sarcomas
• Targeted treatments for SMARCB1/SMARCA4-deficient tumors
• Advancing clinical trials in rare cancers
• Health equity in cancer care for marginalized populations
• Clinical sequencing limitations in genomic profiling
• Cost analysis of sarcoma therapies

Scientific Awards: None listed in the provided text.

Recent Publications highlight expertise in:

• Immune checkpoint inhibitors (e.g., PD-1/CTLA-4 therapies)
• Targeted therapies for sarcomas, thyroid cancer, and gynecologic malignancies
• Cost-effectiveness and accessibility of cancer treatments
• Molecular diagnostics for rare tumors like ameloblastoma and yolk sac tumors
• Health disparities in sexual/gender minority communities